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Abstract
There are no data from West Africa reporting musculoskeletal (MSK) disease in people living with HIV (PLWH). Our pri-
mary outcome was to measure the prevalence of MSK symptoms in PLWH in urban West Africa. Our secondary outcomes 
were to describe the disability, impact on work and treatment use associated with the presence of MSK pain. We conducted 
an e-questionnaire-based point prevalence study of musculoskeletal symptoms, associated disability and treatment in 292 
PLWH attending routine follow-up in Lagos, Nigeria. Seventy-three (25%) patients reported MSK pain; 28 (38%) reported 
chronic symptoms (> 3 months). HIV suppression rates were high in this population (n = 240, 82%) and comparable between 
individuals with and without chronic pain. MSK pain was associated with female gender and higher body mass index (BMI). 
Mechanical pain was the most common pain syndrome identified (n = 34, 47%). Lumbar spine and knee were the most com-
mon sites. Chronic pain was associated with increased disability compared with the presence of any MSK pain. High rates 
of treatment-seeking behaviour were seen in those individuals reporting MSK pain (n = 62, 85%). The majority of these 
individuals sought traditional treatments (n = 48, 66%). Chronic MSK pain and non-prescribed treatments are common in 
PLWH established on ART in urban West Africa. Studies are required to measure the long-term impact of these symptoms 
and medicines on retention in HIV care and ART adherence, besides other long-term health outcomes.
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Introduction
More than 36 million people live with HIV worldwide: 70% 
of this population live in sub-Saharan Africa (SSA) [1]. Life 
expectancy of people living with HIV (PLWH) is increasing 
as early highly active anti-retroviral therapy (HAART) cov-
erage advances [2]. In this ageing population non-commu-
nicable diseases (NCDs) have emerged as the leading causes 
of morbidity and mortality [3]. Globally musculoskeletal 
(MSK) disease is the second leading cause of years lived 
with disability [4].
Arthralgia is a common symptom reported in question-
naire-based studies of MSK disease in PLWH in Europe 
and America, but these data pre-date modern ART treat-
ment programmes [5]. There are also data that associate 
HIV infection with increased incidence of diverse rheumatic 
conditions such as reactive arthritis, psoriatic arthritis and 
osteoporosis [6]. However, high-quality studies describing 
the prevalence of MSK disease in PLWH are absent and 
most data originate from single-centre retrospective studies 
in settings of low HIV prevalence [7]. Contemporary data 
from a single clinic in East Africa suggest that MSK symp-
toms are common in PLWH, however ART uptake was very 
low in this cohort [8]. Besides the virus itself and other risk 
factors in this setting, key ART agents, such as tenofovir and 
protease inhibitor class drugs, are associated with increased 
risk of symptomatic osteoporosis [9].
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The primary aim of our study was to describe the prev-
alence of MSK symptoms in HIV-infected individuals in 
urban West Africa. The study also aimed to describe disabil-
ity associated with MSK pain, HIV risk factors associated 
with MSK pain and treatment-seeking behaviours in indi-
viduals with MSK symptoms. Although Central and West 
Africa account for nearly 20% of the global population of 
PLWH, there are no published data regarding MSK disease 
from this region at all [1]. Our study is the first to describe 
the impact of MSK symptoms on the lives of PLWH in SSA 
and what treatments are used in this setting.
Methods
Study population
This cross-sectional study was conducted at the HIV out-
patient clinic of the Nigerian Institute of Medical Research 
(NIMR) in Lagos, Nigeria from April to August 2017. Eli-
gibility criteria were: documented HIV-1 infection; age 
18 years and above; not currently receiving treatment for 
tuberculosis (TB); willingness to provide informed consent. 
The centre is one of the 25 sentinel centres that commenced 
HIV treatment in Nigeria in 2002. The centre has enrolled 
over 24,000 PLWH in southern Nigeria. Enrolled individuals 
have diverse and representative tribal and socio-economic 
backgrounds for the region; approximately 91.1% have at 
least secondary school education [10]. PLWH managed at 
NIMR attend routine bi-annual outpatient clinic follow-
up. Approximately 300 adults present for outpatient clinic 
follow-up per week. Since June 2016 NIMR have initiated 
ART for all patients diagnosed with HIV infection consistent 
with World Health Organisation (WHO) guidelines [11]. In 
Nigeria approximately one-third of PLWH have suppressed 
HIV infection on ART [12].
Routine follow-up encompasses healthcare worker 
(HCW) delivered health questionnaire, drug history, clinical 
observations (height, weight, body mass index (kg/m2), BP), 
and blood tests (viral load (VL) testing, CD4+ T cell count, 
renal biochemistry). Abnormal renal function was defined 
by GFR < 60 ml/min/1.73 m2. Occupation and skill level 
were defined by the International Standard Classification of 
Occupation [13].
Systematic random sampling was used to select the study 
population: on each clinic day the first ten attending patients 
were numbered and one patient selected by balloting. This 
individual became the first potential study patient of the day 
and every fifth patient on the clinic list became the subse-
quent potential study participants. A tablet-based structured 
e-questionnaire was delivered by local medical officers at the 
time of clinic attendance who would not be directly involved 
in the care of individual participants, but who work in the 
facility and are experienced at delivering similar tools in 
this setting. Five individuals approached to participate were 
not included in the study owing to lack of valid consent or 
missing data.
HIV outcomes
HIV clinical and treatment history, and laboratory data are 
collected routinely in the NIMR database. These data were 
linked to the questionnaire data by hospital number. We 
recorded the immune status [most recent CD4+ T cell count 
(cells/mm3)] and HIV control [HIV-1 VL (copies/ml)] of 
each patient which were all within the 12 months preceding 
study inclusion. Second line ART is defined by the use of 
any protease inhibitors (PIs) in this setting [11]. Suppressed 
VL was defined as < 200 copies/ml.
MSK assessment
Collected data included presence of joint, soft tissue or bone 
pain (defined as MSK pain), joint stiffness, and joint swell-
ing. Duration of symptoms and diurnal patterns (morning, 
rest of day, evening, constant) were collected. Symptoms in 
the week preceding the study defined point prevalence. Two 
groups were defined by the presence (group 1) or absence 
(group 2) of MSK pain. Chronic symptoms were defined as 
duration exceeding 3 months. Pain location was assessed 
using a modified mannequin adapted from the Standardised 
Nordic Questionnaire [14]. Pain severity was assessed using 
the four grades of the Graded Chronic Pain Scale in conjunc-
tion with a visual analogue scale (VAS) [15]. The 12-item 
WHO Disability Assessment Schedule 2.0 (12-item WHO-
DAS2) was used to assess disability [16]. Structured ques-
tions were prepared with local rheumatology physicians for 
setting-specific treatment interventions. ‘Mixing’ describes 
purchase of small bags of mixed non-prescribed unlabelled 
medicines from street hawkers. Self-reported history of 
significant trauma, rheumatoid arthritis (RA) and psoriasis 
were collected. Significant trauma was defined as seeking 
medical or surgical consultation. Local rheumatology phy-
sicians suggest that we limit self-reported diagnoses to RA 
and psoriasis as they are the most common diagnoses seen 
in the two government rheumatology clinics in Lagos [17].
We pre-defined three MSK pain syndromes. We con-
sidered pain to be inflammatory pain if the following three 
criteria were satisfied: pain during the night or early morn-
ing, pain in > 1 joint, morning stiffness ⩾ 60 min. Mechani-
cal pain was defined by the presence of the following three 
criteria: association of pain with use of joint, improvement 
at rest, morning stiffness < 60 min. Arthralgia was defined 
as joint pain in the absence of stiffness or swelling and no 
association with use of joint.
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Those individuals identified with symptoms thought to 
warrant specialist review by the data collector were dis-
cussed with OE and referred to the local government rheu-
matology clinic if indicated.
Data collection and statistical analysis
The Open Data Kit software (http://www.opend ataki t.org/) 
was used to build the e-questionnaire, to collect and col-
late data online and then export these data as CSV files for 
analysis [18]. In collaboration with Nigerian rheumatology 
colleagues, pretesting of the questionnaire was conducted 
by six local medical officers at NIMR in 12 consented clinic 
patients.
The calculated sample size was 246 aimed to detect a 
MSK pain prevalence of 20% based on Z value 1.96 and d 
value 0.05. Assumed prevalence (P) was based at the time of 
study design on the only available COPCORD (Community 
Oriented Program for the Control of Rheumatic Diseases) 
studies in Africa [19].
Statistical analysis was performed using STATA 14.0 
(StataCorp LP, TX, USA). Data were analysed using Chi 
square test for categorical variables (presented as frequen-
cies and percentages) and using Mann–Whitney test for con-
tinuous variables (presented as the median and interquartile 
range, IQR). A p value of < 0.05 was considered significant.
Results
Study population
292 individuals were recruited to the study during routine 
follow-up. The age of the study population ranged between 
18 and 64 years (median 41 years). 65% were female. The 
median BMI of the study population was 25 (IQR 22–28). 
79% of the study population (n = 230) were employed in skill 
level 1 or 2 occupations; 13% were unemployed (n = 39) and 
2% retired (n = 6).
HIV outcomes
Ninety-nine percent of group 1 (pain present group) were 
prescribed ART at the time of the study and 81% had an 
undetectable HIV VL. There was no significant difference 
between individuals with or without pain or chronic pain in 
terms of ART adherence, duration of ART, unsuppressed 
HIV, median CD4+ T cell count and prior treatment for 
TB (Table 1). Tenofovir- and protease inhibitor-containing 
ART regimens were also equally distributed between the 
two groups.
MSK symptoms
Out of 292 individuals recruited for the study, the point preva-
lence of MSK pain was 25% (n = 73). The presence of MSK 
pain was associated with female gender (n = 56, 77%; p = 0.02) 
but not age (p = 0.61). The group with MSK pain (group 1) had 
a significantly higher median BMI compared with the group 
without MSK pain (group 2, pain absent group; p = 0.01). 
Abnormal renal function and concomitant diabetes were not 
associated with MSK pain.
According to pre-determined criteria, four individuals had 
inflammatory pain, 34 (47%) mechanical pain and 14 (19%) 
arthralgia. Location of MSK pain is summarised in Table 2. 
38% of group 1 reported chronic MSK pain. History of sig-
nificant trauma in the preceding 12 months was comparable 
between the two groups (10% and 9% respectively; p = 0.91).
Three individuals reported a pre-existing diagnosis of 
rheumatoid arthritis and no individuals reported pre-existing 
psoriasis diagnosis: none of these patients met the study 
criteria for inflammatory pain.
Ninety-six percent (n = 70) of MSK pain reported was 
grade 1 or 2 using VAS. Three patients (4%) reported grade 
3 pain: two of these individuals had arthralgia, one inflam-
matory pain. The median total disability score for individu-
als reporting any duration MSK pain was 2% (IQR 0–6). 
The median total disability score was significantly higher for 
individuals reporting chronic MSK pain [8% (IQR 0–11.5); 
p < 0.001]. Three individuals with chronic pain (3/28, 11%) 
experienced moderate or severe disability: one individual 
had mechanical pain and two had arthralgia. Six individuals 
with chronic pain (6/28, 21%) reported stopping work due 
to MSK pain.
Management of MSK pain
Eighty-five percent (62/73) of group 1 individuals sought 
treatment for their MSK pain. Sixty-six percent (41/62) of 
treatment-seeking individuals sought non-prescribed tradi-
tional treatments alone; 15% (9/62) sought both traditional 
and conventional medicines. Two individuals consulted a 
specialist rheumatologist; one individual with inflamma-
tory pain was referred to rheumatology services during the 
study. In terms of non-prescribed conventional medicines: 
21% (61/292) of all individuals reported using medicines 
prescribed for other people and 23% (67/292) reported ‘mix-
ing’ unlabelled medicines.
Discussion
In this study in urban West Africa, one quarter of HIV-
infected individuals attending routine clinical follow-up 
reported MSK pain and nearly 40% of this pain was chronic. 
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Table 1  Patient characteristics 
of groups with (group 
1) and without (group 2) 
musculoskeletal pain (group 1)
Values are given as the median (interquartile range) unless otherwise stated. Statistically significant p val-
ues shown in bold
MSK musculoskeletal; chronic pain defined as duration > 3 months, VL viral load
Group 1 (MSK pain) Group 2 (no MSK pain) p value
Total, n (%) 73 (25) 219 (75)
Chronic pain 28 (38)
Age, years 41 (38–48) 42 (37–49) 0.61
Female, n (%) 56 (77) 134 (61) 0.02
BMI 27.5 (22–30) 24.8 (21–28) 0.01
Employed, n (%) 62 (85) 185 (84) 0.86
Prescribed ART, n (%) 72 (99) 211 (96) 0.33
Tenofovir-containing regimen, n (%) 39 (53) 118 (54)
Duration ART (months) 77 (52–122) 91 (54–118) 0.45
CD4+ T cell count (cells/mm3) 525 (363–711) 488 (349–667) 0.35
Detectable HIV VL, n (%) 14 (19) 39 (18) 0.79
Previously treated for TB, n (%) 5 (7) 23 (11) 0.49
History of significant trauma 7 (10) 20 (9) 0.91
Use of mixing, n (%) 13 (18) 53 (24) 0.26
Use of non-prescribed medicines, n (%) 49 (67) 152 (69) 0.72
Use of medicines prescribed for other 
individuals, n (%)
13 (18) 49 (22) 0.41
Sought treatment for MSK pain, n (%) 62 (85)
Herbalist 29
Traditional healer 16
Blood-letter 15
Doctor 12
Pharmacy retailer 8
Surgeon 7
Spiritual healer 3
Rheumatologist 2
Table 2  Overall point 
prevalence and location of 
musculoskeletal pain organised 
by total number of anatomical 
sites and by pre-defined pain 
syndrome groups
Total Mechanical Inflammatory Arthralgia Non-specific
Overall point preva-
lence, n (%)
73 34 (47) 4 (5) 14 (19) 21 (29)
Location, n (% where n > 10)
 Spine
 Neck 3 1 0 2 0
 Thoracic 4 1 1 1 1
 Lumbar 23 (32) 12 (35) 1 1 9
Upper limbs
 Shoulders 8 4 0 4 0
 Elbows 5 2 1 1 1
 Wrists 4 3 0 1 0
 Fingers 2 1 0 0 1
Lower limbs
 Hips 6 5 0 1 0
 Knees 22 (30) 9 2 3 8
 Ankles/feet 13 (18) 8 0 3 2
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Overall this suggests that nearly 10% of all PLWH in this 
population suffer chronic MSK pain. Although reported 
pain severity was mostly mild, disability was significantly 
increased in those individuals reporting chronic MSK pain 
and 21% were forced to stop work owing to their MSK pain. 
A major strength of the study is the fact that it represents the 
first data ever from West Africa to describe the burden of 
MSK symptoms in HIV-infected individuals. Further these 
are the first data from the entire continent of Africa since 
the HIV test and treat era looking at MSK symptom preva-
lence. A further strength of the study was the high rates of 
ART uptake and viral suppression in the study population. 
This makes the data sentinel for the future of HIV care in 
Africa as ART rollout continues and may help inform future 
relevant studies. The findings are similar to an East African 
single-centre study which found 27% prevalence of rheu-
matic manifestations in a cohort of HIV-infected individuals 
with much lower rates of HIV treatment, 21% compared with 
81% in our study [8]. The study is also the first to address the 
disquieting scarcity of data regarding MSK disease and asso-
ciated treatments across Africa. More than two-thirds of the 
population use non-prescribed treatments which is alarm-
ingly high and under-reported in the available literature.
This study suggests that rates of MSK symptoms remain 
high despite effective HIV treatment. Importantly presence 
of MSK pain did not appear to impact ART adherence or 
retention in care. Across SSA, where HIV is most prevalent, 
travel distance from rural settings to urban treatment centres 
is a major barrier to ART adherence [20]. Individuals may 
collect ART on behalf of family members if they are too 
unwell to attend pharmacy. However, this is also associated 
with lower ART adherence and poor clinic attendance itself 
predicts poor outcomes [20]. This study was not powered 
to measure the impact of MSK disease on long-term ART 
adherence and outcomes. Long-term longitudinal studies 
are required to assess whether MSK symptoms and disease 
significantly contribute to poor clinic attendance and HIV 
outcomes across SSA. The study also identified high rates of 
medicine-seeking behaviour in individuals with MSK pain, 
consistent with other regional studies in non-HIV infected 
individuals [21]. In this setting, the potentially deleterious 
drug interactions with ART of both traditional and conven-
tional medicines, such as corticosteroid, also require further 
study.
As a single centre study, these data are not representa-
tive of all PLWH in low and middle income countries 
(LMICs) where rates of HIV diagnosis, ART uptake and 
HIV suppression may be lower. However, since 2016 
WHO have advocated ART initiation for all individu-
als diagnosed with HIV rather than treatment strategies 
guided by immune status (test and treat) [22]. Consist-
ent with this policy, these data are representative of an 
urban African population of PLWH with high rates of 
ART adherence and viral suppression which is the planned 
future for the continent. As ART coverage advances across 
SSA so does life expectancy but also incidence of NCDs. 
It is essential at this time to consider the implications of 
NCDs in these countries where specialist knowledge is sig-
nificantly lacking in order to plan future health care policy 
and provision [23]. Further study is urgently required to 
better characterise the burden of all NCDs and impact on 
long-term HIV care outcomes [18]. The questionnaire did 
not aim to directly capture all possible infectious and non-
infectious co-morbidities that might be associated with 
MSK symptoms in this setting, such as malignancy, and 
the prevalence of these factors may be significantly differ-
ent between our two patient groups, with and without pain.
As a questionnaire-based study there is a risk of 
responder bias. However, the questionnaires were deliv-
ered by medical officers not directly connected to the care 
of the individual study participants which should reduce 
the effect of this problem. It is likely that this study also 
underestimates the burden and severity of MSK disease 
in PLWH in West Africa. The most disabled individuals 
may have been excluded from our study by being unable to 
attend clinic owing to limited mobility. As it was not pos-
sible to include clinical assessment by a specialist rheu-
matologist, this study was also not designed to capture 
specific diagnoses such as fibromyalgia, the prevalence of 
specific diagnoses also necessitates rigorous study.
High-quality epidemiology of MSK and autoimmune 
disease is urgently needed for both HIV-infected and HIV-
uninfected populations across sub-Saharan Africa. The 
tools used to capture MSK data lag behind other fields 
[18]. This study successfully used an interactive open 
access e-questionnaire software which can operate on any 
Android smartphone and could enhance the study of rheu-
matology epidemiology in LMICs. This study points to 
a significant burden of rheumatic morbidity in PLWH in 
West Africa which needs high-quality longitudinal study 
in comparison with an HIV-uninfected cohort to delineate 
the natural history of rheumatic disease in this population, 
potential interaction with HIV and its treatment, and its 
impact on socioeconomic productivity in SSA.
In conclusion, this study suggests that MSK symptoms 
and associated disability are common in PLWH in urban 
west Africa despite high rates of successful ART in the 
test and treat era. Non-prescribed conventional and tradi-
tional treatments are commonly used by PLWH experienc-
ing MSK pain. Further study is required to understand the 
implications of this morbidity and informal therapy on 
HIV outcomes in Africa.
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